TABLE 3.
Measures of capsule compliance
| Parameter | EPA-rich fish oil (n = 39) | DHA-rich fish oil (n = 38) | Placebo (n = 41) | Significance |
|---|---|---|---|---|
| Stopped before visit 2 (self-report) | 3 | 0 | 3 | .24a |
| Compliance between visits 1 and 2 (pill count), mean (SD) [number missing]c | 0.67 (0.25) [3] | 0.78 (0.20) [4] | 0.68 (0.27) [1] | .15b |
| Stopped before visit 3 (self-report) | 4 | 2 | 4 | .77a |
| Compliance between visits 2 and 3 (pill count), mean (SD) [number missing]c | 0.58 (0.32) [5] | 0.65 (0.27) [6] | 0.63 (0.31) [2] | .63b |
| Stopped before visit 5 (self-report) | 5 | 4 | 7 | .75a |
| Compliance between visits 3 and 5 (pill count), mean (SD) [number missing]c | 0.67 (0.35) [4] | 0.62 (0.30) [2] | 0.64 (0.36) [3] | .85b |
Visit 1 was at enrollment at 12–20 weeks, visit 2 was at 26–28 weeks, visit 3 was at 34–36 weeks, and visit 5 was at 6–8 weeks’ postpartum. ANOVA, analysis of variance; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; SD, standard deviation.
a
Fisher exact test;
b
One-way ANOVA;
c
Missing means that the subject did not return capsules to be counted at this time point.